# Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

> **NCT05815758** · PHASE3 · COMPLETED · sponsor: **Bausch & Lomb Incorporated** · enrollment: 512 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)
- **DRUG:** Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution

## Key facts

- **NCT ID:** NCT05815758
- **Lead sponsor:** Bausch & Lomb Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-20
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-09-18
- **Target enrollment:** 512 (ACTUAL)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05815758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05815758, "Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05815758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*